Bladder CancerBOOSTNCT06002269
A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients
A study testing Dietary and Exercise Intervention in people with Bladder Cancer and Cystectomy, run by University of Utah at 1 site in United States.
Trial summary
The purpose of this study is to test a randomized, controlled diet and physical activity intervention designed to be simple and address barriers to participation in lifestyle intervention among 16 urinary bladder cancer patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bladder Cancer, Cystectomy, Chemotherapy
- What is being tested?
- Dietary and Exercise Intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Jun 2024to 8 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients 18 years or older.
- Newly diagnosed urinary bladder cancer patients indicated for cystectomy with or without neo-adjuvant therapy; Treated with surgery at the Huntsman Cancer Institute
- Have reliable, consistence access to the internet for study procedures
- Inclusion of Individuals across the Lifespan: The proposed trial will enroll 20 adults who have been diagnosed with bladder cancer. The age range of participants to be recruited is 18 years or older. Bladder cancer is generally a disease of older age and is exceedingly rare in children. According to the American Cancer Society, average age at diagnosis is 73.1 Therefore, we are unable to include children in this trial.
- Inclusion of Women, Minorities, and Children: It is anticipated that 20% will be female; 80% male. Racial distribution is projected to be as follows: 97% white, 1% Native Hawaiian or Pacific Islander; 1% American Indian/ Alaska Native; 1% Asian; <1% Black. Approximately 96% will be Non-Hispanic.
Who cannot join
- Special dietary requirements (i.e., allergies and intolerances, or other clinically prescribed diet).
- Unable to provide informed consent or read, write, or fill in questionnaires in English
Trial locations and contacts
1 site in 1 country.
United States1 site
Huntsman Cancer Institute
Salt Lake City, Utah, 84112
About this study
Official title: A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients: the BOOST Study
The purpose of this study is to test a randomized, controlled diet and physical activity intervention designed to be simple and address barriers to participation in lifestyle intervention among 16 urinary bladder cancer patients.
Aim 1 is to test the feasibility and acceptability of a novel, peri-operative lifestyle intervention, "The Boost Box", among bladder cancer patients receiving cystectomy with or without neo-adjuvant chemotherapy.
Read more
Aim 2 is to measure the feasibility of collecting data on the intervention effects on complication rate, nutritional status, weight loss, and quality of life post-surgery among bladder cancer patients receiving cystectomy ± neoadjuvant therapy. Secondarily, we will determine the magnitude of association between study group and outcomes to inform power calculations in a future, well-powered trial.
Participants will:
- attend two dietetic consultations at baseline and post-surgical recovery where nutritional status will be evaluated with patient-generated subjective global assessment (PG-SGA)
- complete baseline questionnaires (TCC, FACT-BI-Cys, Short 2012, FAACT, Godin)
- receive weekly BOOST boxes
- complete pre-surgery weekly BOOST check ins
- complete post-surgery weekly BOOST check ins
- complete an ASA food recall pre and post-surgery
- complete an exercise familiarization consult
- record weekly resistance and aerobic exercise performed at home
- complete a 6 month follow-up questionnaire
- receive compensation
Researchers will compare to a Usual Care group to determine differences that could be attributed to the BOOST Box intervention.
Read the detailed description
Urinary bladder cancer is the fourth leading cancer in men in the US, leading to 18,000 deaths among men and women annually.1 The survival rate is 69% for localized disease, 36% for regional disease, and only 5% for metastatic disease.2 Bladder cancer patients often present with non-muscle invasive bladder cancer (NMIBC) and are treated with chemotherapy or immunotherapy delivered locally in the bladder. Patients with muscle- invasive bladder cancer or intravesical therapy-refractory disease undergo cystectomy. Weight loss, frailty, sarcopenia, and malnutrition are commonplace among urinary bladder cancer patients, all being associated with treatment-related complications including susceptibility to infection, poor prognosis and quality of life.3 Medical nutrition therapy is indicated in this population that generally has poor diet quality4-7 to achieve or maintain a healthy body weight, preserve lean body mass, minimize nutrition-related side effects, and maximize quality of life.8-10 Yet, only a handful of dietary interventions have been conducted among urinary bladder cancer patients, and no studies of diet intervention coupled with exercise prescription, with the goal of improving treatment outcomes in this population. Pre- and postoperative nutrition support has been linked to reduced hospital length of stay,11 and lower postoperative complications like infection. Immunonutrition interventions, which comprise of supplements or food/drinks high in vitamin A, fish oil or omega-3 fatty acids, and specific amino acids like arginine, have also been shown to lower postoperative complications in cystectomy patients and other cancer populations.12-15 In patients receiving chemotherapy or radiation, immunonutrition also appears to reduce mucositis and weight loss.16 Furthermore, resistance exercise promotes maintenance or increase in muscle mass, particularly among individuals with sarcopenia.17
Little is known about the trajectory of dietary intake after bladder cancer diagnosis, and the specific nutritional needs of this population in diverse settings where health disparities exist, such as among rural or socio- economically disadvantaged patients.18 There is also a critical need to develop and test interventions that are simple, scalable, durable, and cost-effective,4, 19 and that address food insecurity.20 Given these major research gaps, we will implement a novel, peri-operative lifestyle intervention rooted in Social Cognitive Theory (SCT)21, 22 that uses food/ingredient, menu and recipe provision coupled with resistance exercise recommendations and tools provided in the "Boost Box", mailed to participants over 12-weeks. The intervention builds self-efficacy and behavioral capability in preparing meals to support nutrition goals and addresses social determinants of health in underserved populations by tackling food insecurity.23 Community partnerships will build the foundation for scaling up lifestyle intervention for cancer patients in Utah. Expanding the availability of evidence-based options for nutrition and physical activity counseling for cancer patients and survivors has been identified as a major need.24 Our proposed study is multidisciplinary and community-focused by partnering with the University of Utah Center for Community Nutrition and their established partners (e.g., Waste Less Solutions, Wasatch Community Gardens, Food Recovery Network, Utah Food Bank, Dairy West, and commercial grocers like Smiths and Harmons) to roll out the intervention in the community. Indeed, community and home-based lifestyle interventions improve physical functioning and clinical outcomes among cancer survivors and are cost-effective.25, 26 Delivering diet and physical activity education using a home-based 'Blue Apron' type approach in partnership with the community is highly novel.
Urinary bladder cancer is the fourth leading cancer in men in the US and accounts for over 18,000 deaths among both men and women annually.1 About three quarters of bladder cancer patients present with non- muscle invasive bladder cancer and are treated with chemotherapy or immunotherapy delivered locally in the bladder, or cystectomy alone in intravesical-refractory or extensive disease. Muscle-invasive bladder cancer treatment includes neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. Cisplatin- ineligible patients proceed with cystectomy and those who are too sick or frail for cystectomy receive chemotherapy followed by local radiation. Weight loss is a common occurrence post-radical cystectomy, and is associated with malnutrition3 and poor overall survival.34 Moreover, up to 70% of bladder cancer patients, particularly those with frailty, present with sarcopenia, a condition of reduced skeletal muscle mass and function that is an independent poor prognostic factor35 linked to medical complications and quality of life.36 In all, this population has a 60% complication rate by 90-days,37 from urinary tract infections to bowel obstruction.
Nutrition is a vital component of chemotherapy tolerability and preparation for and recovery after cystectomy38 to prevent or resolve nutrient deficiencies, achieve or maintain a healthy body weight, preserve lean body mass, minimize nutrition-related side effects, and maximize quality of life.4, 8-10, 39 Diet quality is generally poor among adult cancer survivors in the United States.4 Bladder cancer is especially prevalent in developed countries with Western style dietary patterns and high levels of obesity,2, 40 with significant socioeconomic and geographic disparities observed.18, 41 Indeed, rural compared with urban residence is associated with elevated cancer-specific and other cause mortality among bladder cancer survivors.41 In addition, improvement in diet quality among cancer survivors undergoing dietary intervention has been found to be smaller in rural than urban patients. Yet, despite the biologically plausible role of diet in the etiology of bladder cancer, and the potent effects of treatment on nutritional status and weight loss in this population, remarkably few studies have evaluated either pre- or post-diagnosis diet in association with outcomes after bladder cancer diagnosis, nor implemented dietary intervention among bladder cancer patients to optimize their treatment outcomes.42
We will address this immense research gap by testing a randomized, controlled diet and physical activity trial designed to address barriers to participation in lifestyle intervention among 16 urinary bladder cancer patients (50% rural; 50% no college education). Baseline and post-surgical recovery nutritional status will be evaluated with patient-generated subjective global assessment (PG-SGA).43, 44 Diet will be assessed with 3-day food record during the first 6-months post-diagnosis. In the intervention arm, patients will be mailed a "Boost Box" weekly for 6-weeks before and 6-weeks after surgery, prepared by our community partners, containing food ingredients. We will work with the University of Utah Center for Community Nutrition to mail curriculum boxes with a menu and recipes for a high protein, immunonutrition-tailored diet (i.e., arginine, vitamin A, and omega-3 rich foods/beverages), and resistance bands (Theraband) with strength training guidelines.3,
- Conditions
- Bladder Cancer, Cystectomy, Chemotherapy
- Being tested
- Dietary and Exercise Intervention
- Keywords
- Surgery, Weight Loss, Urinary, Lifestyle, Cystectomy, Malnutrition, Chemotherapy, Diet, Exercise
- Medical subject headings
- Urinary Bladder Neoplasms, Weight Loss, Malnutrition, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietary and Exercise InterventionCombination product
Participants will receive food ingredients and recipes to be made and consumed for each meal, every day for a period of 3-6 weeks before surgery and 6-weeks after surgery. The menu is designed as a high protein, high calorie diet meeting targets for omega-3 fatty acids, vitamin A, and arginine (immunonutrition meal plan). In addition, participants will receive an individualized exercise prescription to be performed at home using theraband resistance bands.
| Study group | Role | What they receive |
|---|---|---|
| BOOST Box Intervention | Experimental | Baseline: Questionnaires (FACT-Bl-Cys, mPG-SGA, Short 2012, FAACT, Godin, TCC), exercise prescription, compensation.
Pre-Surgery: Dietitian consultation, at least 3-weeks and up to 6-weeks of Boost Box deliveries and check-ins (nutritional intervention), up to 6 weeks of exercise intervention and logs, ASA Food Record (x2), compensation Post-Surgery: post-surgery surveys once (FACT-Bl-Cys, mPG-SGA, FAACT, Godin), 6 weeks of Boost Box deliveries and check-ins (nutritional intervention), 6 weeks of exercise intervention and logs, weekly hunger check-in, ASA Food Record (x2), Dietitian consultation, compensation.
Follow-up (estimated 6 months after baseline) : 6-month questionnaire, compensation.
Compensation total: up to $100 via electronic gift card. Receives: Combination Product: Dietary and Exercise Intervention |
| Usual Care | No intervention | Baseline: Questionnaires (FACT-Bl-Cys, mPG-SGA, Short 2012, FAACT, Godin, TCC), compensation. Pre-Surgery: Dietitian consultation, ASA Food Record (x2), compensation. Post-Surgery: post-surgery surveys once (FACT-Bl-Cys, mPG-SGA, FAACT, Godin), Dietitian consultation, ASA Food Record (x2), compensation. Follow-up (estimated 6 months after baseline): 6-month questionnaire, compensation. Compensation total: up to $100 via electronic gift card. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of BOOST Box Intervention
Feasibility of a novel, peri-operative lifestyle intervention, "The Boost Box", among bladder cancer patients receiving cystectomy with or without neo-adjuvant chemotherapy.
Feasibility metrics include: % consented/referred; attrition as a function of time; % questionnaires completed; % meals prepared and consumed. Feasibility criteria: >70% patients consented and retained; completed all questionnaires; prepared/consumed Boost Box meals ≥5/7 days/week; and adhered to resistance band exercise ≥2 days/week. Fidelity criteria: 90% protocol checklist items delivered as intended.
Measured: From enrollment to the 6-month follow-up survey
Acceptability of BOOST Box Intervention
Acceptability of a novel, peri-operative lifestyle intervention, "The Boost Box", among bladder cancer patients receiving cystectomy with or without neo-adjuvant chemotherapy.
Acceptability of the intervention delivery and menus/recipes will be evaluated by administering an anonymous questionnaire incorporating both Likert scale questions and space for open-ended responses.
Measured: From enrollment to the 6-month follow-up survey
Secondary outcomes (4)
Malnutrition assessment
Surveys and Questionnaires used will be the Modified Patient-Generated Subjective Global Assessment (mPG-SGA), Functional Assessment of Anorexia and Cachexia Therapy (FAACT), U.S.Household Food Security Survey Module: Six Item Short Form (Short 2012), and Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24) food consumption log to calculate a Healthy Eating Index (HEI) which will define diet quality (a higher score indicates a healthier diet).
Measured: mPG-SGA, FAACT, and Short 2012 at baseline and then mPG-SGA and FAACT again six weeks post-surgery. ASA24 during six weeks pre and post-surgery
Surgical complication rate
The following information is to be abstracted from medical charts: 30- and 90-day post-surgery complication rates including wound infections; Urinary Tract Infection (UTI); infectious complications; blood clots; readmissions; failure to thrive; dehydration; re-operations.
Measured: 30 and 60 days post-surgery
Body weight
Participant weight measurements will be collected through participant self-reporting using a digital scale provided by the study and through medical record abstraction.
Measured: From enrollment to the 6-month follow-up survey
Quality of Life (Physical, social, emotional, functional well-being, and a bladder cancer subscale)
Questionnaire used will be the Functional Assessment of Cancer Therapy - Bladder - Cystectomy (FACT-Bl-Cys).
Measured: FACT-BI-Cys used from baseline to the 6-month follow-up survey
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2023
- Study start4 Jun 2024
- Primary completion8 Jul 2025
- Study completion8 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (42)Papers the sponsor has linked to this study.
- Other trials for Bladder CancerStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- BOOST Box intervention compared with usual care.
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mary C Playdon, PhD, MPH, Principal investigator, University of Utah NUIP Department and Huntsman Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06002269
- Sponsor's protocol ID
- HCI150155
- Acronym
- BOOST
- Status last verified
- Jul 2025
- First submitted
- 15 Aug 2023
- Last updated
- 20 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
PubMed 31912902Tobert CM, Hamilton-Reeves JM, Norian LA, Hung C, Brooks NA, Holzbeierlein JM, Downs TM, Robertson DP, Grossman R, Nepple KG. Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications for Cystectomy in Bladder Cancer. J Urol. 2017 Sep;198(3):511-519. doi: 10.1016/j.juro.2017.01.087. Epub 2017 Mar 9.
PubMed 28286066Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ Jr, Aghazadeh M, Smith JA Jr, Barocas DA. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol. 2011 Jan;185(1):90-6. doi: 10.1016/j.juro.2010.09.021. Epub 2010 Nov 12.
PubMed 21074802Hansen TTD, Omland LH, von Heymann A, Johansen C, Clausen MB, Suetta C, Pappot H, Rafn BS. Development of Sarcopenia in Patients With Bladder Cancer: A Systematic Review. Semin Oncol Nurs. 2021 Feb;37(1):151108. doi: 10.1016/j.soncn.2020.151108. Epub 2021 Jan 8.
PubMed 33431235Grimberg DC, Shah A, Molinger J, Whittle J, Gupta RT, Wischmeyer PE, McDonald SR, Inman BA. Assessments of frailty in bladder cancer. Urol Oncol. 2020 Sep;38(9):698-705. doi: 10.1016/j.urolonc.2020.04.036. Epub 2020 May 22.
PubMed 32451229Maibom SL, Joensen UN, Poulsen AM, Kehlet H, Brasso K, Roder MA. Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open. 2021 Apr 14;11(4):e043266. doi: 10.1136/bmjopen-2020-043266.
PubMed 33853799Jensen BT, Lauridsen SV, Jensen JB. Optimal Delivery of Follow-Up Care After Radical Cystectomy for Bladder Cancer. Res Rep Urol. 2020 Oct 14;12:471-486. doi: 10.2147/RRU.S270240. eCollection 2020.
PubMed 33117747Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012 Jul-Aug;62(4):243-74. doi: 10.3322/caac.21142. Epub 2012 Apr 26.
PubMed 22539238Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):366-380. doi: 10.1002/jcsm.12525. Epub 2020 Jan 8.
PubMed 31916411Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6.
PubMed 27637832Keaver L, Houlihan C, O'Callaghan N, LaVertu AE, Ding X, Zhang FF. Evidence-based nutrition guidelines for cancer survivors in Europe: a call for action. Eur J Clin Nutr. 2022 Jun;76(6):819-826. doi: 10.1038/s41430-021-01036-8. Epub 2021 Oct 29.
PubMed 34716363Demark-Wahnefried W, Rogers LQ, Alfano CM, Thomson CA, Courneya KS, Meyerhardt JA, Stout NL, Kvale E, Ganzer H, Ligibel JA. Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin. 2015 May-Jun;65(3):167-89. doi: 10.3322/caac.21265. Epub 2015 Feb 13.
PubMed 25683894Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. Med Sci (Basel). 2020 Mar 13;8(1):15. doi: 10.3390/medsci8010015.
PubMed 32183076Jochems SHJ, Van Osch FHM, Bryan RT, Wesselius A, van Schooten FJ, Cheng KK, Zeegers MP. Impact of dietary patterns and the main food groups on mortality and recurrence in cancer survivors: a systematic review of current epidemiological literature. BMJ Open. 2018 Feb 19;8(2):e014530. doi: 10.1136/bmjopen-2016-014530.
PubMed 29459359Lee E, Zhu J, Velazquez J, Bernardo R, Garcia J, Rovito M, Hines RB. Evaluation of Diet Quality Among American Adult Cancer Survivors: Results From 2005-2016 National Health and Nutrition Examination Survey. J Acad Nutr Diet. 2021 Feb;121(2):217-232. doi: 10.1016/j.jand.2020.08.086. Epub 2020 Nov 3.
PubMed 33158797
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients: the BOOST Study
- ClinicalTrials.gov ID
- NCT06002269
- Acronym / sponsor ID
- BOOST / HCI150155
- Conditions
- Bladder Cancer, Cystectomy, Chemotherapy
- Keywords
- Surgery, Weight Loss, Urinary, Lifestyle, Cystectomy, Malnutrition, Chemotherapy, Diet
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 8 participants (actual)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Study start
- 4 Jun 2024 (actual)
- Primary completion
- 8 Jul 2025 (actual)
- Study completion
- 8 Jul 2025 (actual)
- First posted
- 21 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test a randomized, controlled diet and physical activity intervention designed to be simple and address barriers to participation in lifestyle intervention among 16 urinary bladder cancer patients.
Aim 1 is to test the feasibility and acceptability of a novel, peri-operative lifestyle intervention, "The Boost Box", among bladder cancer patients receiving cystectomy with or without neo-adjuvant chemotherapy.
Aim 2 is to measure the feasibility of collecting data on the intervention effects on complication rate, nutritional status, weight loss, and quality of life post-surgery among bladder cancer patients receiving cystectomy ± neoadjuvant therapy. Secondarily, we will determine the magnitude of association between study group and outcomes to inform power calculations in a future, well-powered trial.
Participants will:
- attend two dietetic consultations at baseline and post-surgical recovery where nutritional status will be evaluated with patient-generated subjective global assessment (PG-SGA)
- complete baseline questionnaires (TCC, FACT-BI-Cys, Short 2012, FAACT, Godin)
- receive weekly BOOST boxes
- complete pre-surgery weekly BOOST check ins
- complete post-surgery weekly BOOST check ins
- complete an ASA food recall pre and post-surgery
- complete an exercise familiarization consult
- record weekly resistance and aerobic exercise performed at home
- complete a 6 month follow-up questionnaire
- receive compensation
Researchers will compare to a Usual Care group to determine differences that could be attributed to the BOOST Box intervention.
Detailed description
Urinary bladder cancer is the fourth leading cancer in men in the US, leading to 18,000 deaths among men and women annually.1 The survival rate is 69% for localized disease, 36% for regional disease, and only 5% for metastatic disease.2 Bladder cancer patients often present with non-muscle invasive bladder cancer (NMIBC) and are treated with chemotherapy or immunotherapy delivered locally in the bladder. Patients with muscle- invasive bladder cancer or intravesical therapy-refractory disease undergo cystectomy. Weight loss, frailty, sarcopenia, and malnutrition are commonplace among urinary bladder cancer patients, all being associated with treatment-related complications including susceptibility to infection, poor prognosis and quality of life.3 Medical nutrition therapy is indicated in this population that generally has poor diet quality4-7 to achieve or maintain a healthy body weight, preserve lean body mass, minimize nutrition-related side effects, and maximize quality of life.8-10 Yet, only a handful of dietary interventions have been conducted among urinary bladder cancer patients, and no studies of diet intervention coupled with exercise prescription, with the goal of improving treatment outcomes in this population. Pre- and postoperative nutrition support has been linked to reduced hospital length of stay,11 and lower postoperative complications like infection. Immunonutrition interventions, which comprise of supplements or food/drinks high in vitamin A, fish oil or omega-3 fatty acids, and specific amino acids like arginine, have also been shown to lower postoperative complications in cystectomy patients and other cancer populations.12-15 In patients receiving chemotherapy or radiation, immunonutrition also appears to reduce mucositis and weight loss.16 Furthermore, resistance exercise promotes maintenance or increase in muscle mass, particularly among individuals with sarcopenia.17
Little is known about the trajectory of dietary intake after bladder cancer diagnosis, and the specific nutritional needs of this population in diverse settings where health disparities exist, such as among rural or socio- economically disadvantaged patients.18 There is also a critical need to develop and test interventions that are simple, scalable, durable, and cost-effective,4, 19 and that address food insecurity.20 Given these major research gaps, we will implement a novel, peri-operative lifestyle intervention rooted in Social Cognitive Theory (SCT)21, 22 that uses food/ingredient, menu and recipe provision coupled with resistance exercise recommendations and tools provided in the "Boost Box", mailed to participants over 12-weeks. The intervention builds self-efficacy and behavioral capability in preparing meals to support nutrition goals and addresses social determinants of health in underserved populations by tackling food insecurity.23 Community partnerships will build the foundation for scaling up lifestyle intervention for cancer patients in Utah. Expanding the availability of evidence-based options for nutrition and physical activity counseling for cancer patients and survivors has been identified as a major need.24 Our proposed study is multidisciplinary and community-focused by partnering with the University of Utah Center for Community Nutrition and their established partners (e.g., Waste Less Solutions, Wasatch Community Gardens, Food Recovery Network, Utah Food Bank, Dairy West, and commercial grocers like Smiths and Harmons) to roll out the intervention in the community. Indeed, community and home-based lifestyle interventions improve physical functioning and clinical outcomes among cancer survivors and are cost-effective.25, 26 Delivering diet and physical activity education using a home-based 'Blue Apron' type approach in partnership with the community is highly novel.
Urinary bladder cancer is the fourth leading cancer in men in the US and accounts for over 18,000 deaths among both men and women annually.1 About three quarters of bladder cancer patients present with non- muscle invasive bladder cancer and are treated with chemotherapy or immunotherapy delivered locally in the bladder, or cystectomy alone in intravesical-refractory or extensive disease. Muscle-invasive bladder cancer treatment includes neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. Cisplatin- ineligible patients proceed with cystectomy and those who are too sick or frail for cystectomy receive chemotherapy followed by local radiation. Weight loss is a common occurrence post-radical cystectomy, and is associated with malnutrition3 and poor overall survival.34 Moreover, up to 70% of bladder cancer patients, particularly those with frailty, present with sarcopenia, a condition of reduced skeletal muscle mass and function that is an independent poor prognostic factor35 linked to medical complications and quality of life.36 In all, this population has a 60% complication rate by 90-days,37 from urinary tract infections to bowel obstruction.
Nutrition is a vital component of chemotherapy tolerability and preparation for and recovery after cystectomy38 to prevent or resolve nutrient deficiencies, achieve or maintain a healthy body weight, preserve lean body mass, minimize nutrition-related side effects, and maximize quality of life.4, 8-10, 39 Diet quality is generally poor among adult cancer survivors in the United States.4 Bladder cancer is especially prevalent in developed countries with Western style dietary patterns and high levels of obesity,2, 40 with significant socioeconomic and geographic disparities observed.18, 41 Indeed, rural compared with urban residence is associated with elevated cancer-specific and other cause mortality among bladder cancer survivors.41 In addition, improvement in diet quality among cancer survivors undergoing dietary intervention has been found to be smaller in rural than urban patients. Yet, despite the biologically plausible role of diet in the etiology of bladder cancer, and the potent effects of treatment on nutritional status and weight loss in this population, remarkably few studies have evaluated either pre- or post-diagnosis diet in association with outcomes after bladder cancer diagnosis, nor implemented dietary intervention among bladder cancer patients to optimize their treatment outcomes.42
We will address this immense research gap by testing a randomized, controlled diet and physical activity trial designed to address barriers to participation in lifestyle intervention among 16 urinary bladder cancer patients (50% rural; 50% no college education). Baseline and post-surgical recovery nutritional status will be evaluated with patient-generated subjective global assessment (PG-SGA).43, 44 Diet will be assessed with 3-day food record during the first 6-months post-diagnosis. In the intervention arm, patients will be mailed a "Boost Box" weekly for 6-weeks before and 6-weeks after surgery, prepared by our community partners, containing food ingredients. We will work with the University of Utah Center for Community Nutrition to mail curriculum boxes with a menu and recipes for a high protein, immunonutrition-tailored diet (i.e., arginine, vitamin A, and omega-3 rich foods/beverages), and resistance bands (Theraband) with strength training guidelines.3,
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (care provider)
- Number of arms
- 2
- Model description
- BOOST Box intervention compared with usual care.
| Arm | Type | Receives |
|---|---|---|
| BOOST Box Intervention | Experimental | Combination Product: Dietary and Exercise InterventionBaseline: Questionnaires (FACT-Bl-Cys, mPG-SGA, Short 2012, FAACT, Godin, TCC), exercise prescription, compensation. Pre-Surgery: Dietitian consultation, at least 3-weeks and up to 6-weeks of Boost Box deliveries and check-ins (nutritional intervention), up to 6 weeks of exercise intervention and logs, ASA Food Record (x2), compensation Post-Surgery: post-surgery surveys once (FACT-Bl-Cys, mPG-SGA, FAACT, Godin), 6 weeks of Boost Box deliveries and check-ins (nutritional intervention), 6 weeks of exercise intervention and logs, weekly hunger check-in, ASA Food Record (x2), Dietitian consultation, compensation. Follow-up (estimated 6 months after baseline) : 6-month questionnaire, compensation. Compensation total: up to $100 via electronic gift card. |
| Usual Care | No intervention | –Baseline: Questionnaires (FACT-Bl-Cys, mPG-SGA, Short 2012, FAACT, Godin, TCC), compensation. Pre-Surgery: Dietitian consultation, ASA Food Record (x2), compensation. Post-Surgery: post-surgery surveys once (FACT-Bl-Cys, mPG-SGA, FAACT, Godin), Dietitian consultation, ASA Food Record (x2), compensation. Follow-up (estimated 6 months after baseline): 6-month questionnaire, compensation. Compensation total: up to $100 via electronic gift card. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adult patients 18 years or older.
- Newly diagnosed urinary bladder cancer patients indicated for cystectomy with or without neo-adjuvant therapy; Treated with surgery at the Huntsman Cancer Institute
- Have reliable, consistence access to the internet for study procedures
- Inclusion of Individuals across the Lifespan: The proposed trial will enroll 20 adults who have been diagnosed with bladder cancer. The age range of participants to be recruited is 18 years or older. Bladder cancer is generally a disease of older age and is exceedingly rare in children. According to the American Cancer Society, average age at diagnosis is 73.1 Therefore, we are unable to include children in this trial.
- Inclusion of Women, Minorities, and Children: It is anticipated that 20% will be female; 80% male. Racial distribution is projected to be as follows: 97% white, 1% Native Hawaiian or Pacific Islander; 1% American Indian/ Alaska Native; 1% Asian; <1% Black. Approximately 96% will be Non-Hispanic.
Key exclusion criteria (2 listed)
- Special dietary requirements (i.e., allergies and intolerances, or other clinically prescribed diet).
- Unable to provide informed consent or read, write, or fill in questionnaires in English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietary and Exercise InterventionParticipants will receive food ingredients and recipes to be made and consumed for each meal, every day for a period of 3-6 weeks before surgery and 6-weeks after surgery. The menu is designed as a high protein, high calorie diet meeting targets for omega-3 fatty acids, vitamin A, and arginine (immunonutrition meal plan). In addition, participants will receive an individualized exercise prescription to be performed at home using theraband resistance bands. | Combination product | BOOST Box Intervention |
Primary outcome
Feasibility of BOOST Box Intervention
Time frame: From enrollment to the 6-month follow-up survey
Feasibility of a novel, peri-operative lifestyle intervention, "The Boost Box", among bladder cancer patients receiving cystectomy with or without neo-adjuvant chemotherapy. Feasibility metrics include: % consented/referred; attrition as a function of time; % questionnaires completed; % meals prepared and consumed. Feasibility criteria: >70% patients consented and retained; completed all questionnaires; prepared/consumed Boost Box meals ≥5/7 days/week; and adhered to resistance band exercise ≥2 days/week. Fidelity criteria: 90% protocol checklist items delivered as intended.
Acceptability of BOOST Box Intervention
Time frame: From enrollment to the 6-month follow-up survey
Acceptability of a novel, peri-operative lifestyle intervention, "The Boost Box", among bladder cancer patients receiving cystectomy with or without neo-adjuvant chemotherapy. Acceptability of the intervention delivery and menus/recipes will be evaluated by administering an anonymous questionnaire incorporating both Likert scale questions and space for open-ended responses.
4 secondary outcomes
Malnutrition assessment
Time frame: mPG-SGA, FAACT, and Short 2012 at baseline and then mPG-SGA and FAACT again six weeks post-surgery. ASA24 during six weeks pre and post-surgery
Surgical complication rate
Time frame: 30 and 60 days post-surgery
Body weight
Time frame: From enrollment to the 6-month follow-up survey
Quality of Life (Physical, social, emotional, functional well-being, and a bladder cancer subscale)
Time frame: FACT-BI-Cys used from baseline to the 6-month follow-up survey
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2025.
- Background: PubMed 31912902Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
- Background: PubMed 28286066Tobert CM, Hamilton-Reeves JM, Norian LA, Hung C, Brooks NA, Holzbeierlein JM, Downs TM, Robertson DP, Grossman R, Nepple KG. Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications for Cystectomy in Bladder Cancer. J Urol. 2017 Sep;198(3):511-519. doi: 10.1016/j.juro.2017.01.087. Epub 2017 Mar 9.
- Background: PubMed 21074802Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ Jr, Aghazadeh M, Smith JA Jr, Barocas DA. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol. 2011 Jan;185(1):90-6. doi: 10.1016/j.juro.2010.09.021. Epub 2010 Nov 12.
- Background: PubMed 33431235Hansen TTD, Omland LH, von Heymann A, Johansen C, Clausen MB, Suetta C, Pappot H, Rafn BS. Development of Sarcopenia in Patients With Bladder Cancer: A Systematic Review. Semin Oncol Nurs. 2021 Feb;37(1):151108. doi: 10.1016/j.soncn.2020.151108. Epub 2021 Jan 8.
- Background: PubMed 32451229Grimberg DC, Shah A, Molinger J, Whittle J, Gupta RT, Wischmeyer PE, McDonald SR, Inman BA. Assessments of frailty in bladder cancer. Urol Oncol. 2020 Sep;38(9):698-705. doi: 10.1016/j.urolonc.2020.04.036. Epub 2020 May 22.
- Background: PubMed 33853799Maibom SL, Joensen UN, Poulsen AM, Kehlet H, Brasso K, Roder MA. Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open. 2021 Apr 14;11(4):e043266. doi: 10.1136/bmjopen-2020-043266.
- Background: PubMed 33117747Jensen BT, Lauridsen SV, Jensen JB. Optimal Delivery of Follow-Up Care After Radical Cystectomy for Bladder Cancer. Res Rep Urol. 2020 Oct 14;12:471-486. doi: 10.2147/RRU.S270240. eCollection 2020.
- Background: PubMed 22539238Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012 Jul-Aug;62(4):243-74. doi: 10.3322/caac.21142. Epub 2012 Apr 26.
- Background: PubMed 31916411Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):366-380. doi: 10.1002/jcsm.12525. Epub 2020 Jan 8.
- Background: PubMed 27637832Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6.
- Background: PubMed 34716363Keaver L, Houlihan C, O'Callaghan N, LaVertu AE, Ding X, Zhang FF. Evidence-based nutrition guidelines for cancer survivors in Europe: a call for action. Eur J Clin Nutr. 2022 Jun;76(6):819-826. doi: 10.1038/s41430-021-01036-8. Epub 2021 Oct 29.
- Background: PubMed 25683894Demark-Wahnefried W, Rogers LQ, Alfano CM, Thomson CA, Courneya KS, Meyerhardt JA, Stout NL, Kvale E, Ganzer H, Ligibel JA. Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin. 2015 May-Jun;65(3):167-89. doi: 10.3322/caac.21265. Epub 2015 Feb 13.
- Individual participant dataSharing planned: No
Related trials for Bladder Cancer
RecruitingPhase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Active, not recruitingPhase 2
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor
RecruitingPhase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
RecruitingPhase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mary C Playdon, PhD, MPH principal investigator
University of Utah NUIP Department and Huntsman Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dietary and Exercise Intervention in people with Bladder Cancer and Cystectomy, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of BOOST Box Intervention (time frame: From enrollment to the 6-month follow-up survey). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06002269, which also lists 42 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2025; AzTrials last refreshed its copy on 2 Nov 2026.